197 related articles for article (PubMed ID: 22186083)
1. The value of [18F]fluorodeoxyglucose-PET/CT in oesophageal cancer.
Rankin S
Cancer Imaging; 2011 Oct; 11 Spec No A(1A):S156-60. PubMed ID: 22186083
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
You JJ; Wong RK; Darling G; Gulenchyn K; Urbain JL; Evans WK
J Thorac Oncol; 2013 Dec; 8(12):1563-9. PubMed ID: 24389439
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography in the staging of esophageal cancer.
Leccisotti L
Rays; 2006; 31(1):9-12. PubMed ID: 16999368
[TBL] [Abstract][Full Text] [Related]
5. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).
Cameron K; Golan S; Simpson W; Peti S; Roayaie S; Labow D; Kostakoglu L
Abdom Imaging; 2011 Aug; 36(4):463-71. PubMed ID: 21465110
[TBL] [Abstract][Full Text] [Related]
6. Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?
Torrance AD; Almond LM; Fry J; Wadley MS; Lyburn ID
Surgeon; 2015 Feb; 13(1):19-33. PubMed ID: 24206935
[TBL] [Abstract][Full Text] [Related]
7. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of novel ¹⁸F-FDG PET/CT defined tumour variables in patients with oesophageal cancer.
Foley KG; Fielding P; Lewis WG; Karran A; Chan D; Blake P; Roberts SA
Eur J Radiol; 2014 Jul; 83(7):1069-1073. PubMed ID: 24794862
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
Fuster D; Mayoral M; Rubello D; Pineda E; Fernández-Esparrach G; Pagès M; Colletti PM; Pons F
Clin Nucl Med; 2015 Mar; 40(3):e201-7. PubMed ID: 25546207
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of FDG-PET for the management of esophageal cancer: review article.
Kato H; Nakajima M
Ann Thorac Cardiovasc Surg; 2012; 18(5):412-9. PubMed ID: 22785452
[TBL] [Abstract][Full Text] [Related]
12. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
13. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
[TBL] [Abstract][Full Text] [Related]
14. Advantages of positron emission tomography-computed tomography imaging in esophageal squamous cell carcinoma.
Wang F; Shen LY; Ma SH; Li N; Yang Z; Chen KN
Dis Esophagus; 2013; 26(8):832-7. PubMed ID: 22947128
[TBL] [Abstract][Full Text] [Related]
15. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
Chowdhury FU; Bradley KM; Gleeson FV
Clin Radiol; 2008 Dec; 63(12):1297-309. PubMed ID: 18996259
[TBL] [Abstract][Full Text] [Related]
16. PET and PET-CT in esophageal and gastric cancer.
Wieder HA; Krause BJ; Herrmann K
Methods Mol Biol; 2011; 727():59-76. PubMed ID: 21331929
[TBL] [Abstract][Full Text] [Related]
17. Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
Gillies RS; Middleton MR; Maynard ND; Bradley KM; Gleeson FV
Eur Radiol; 2011 Feb; 21(2):274-80. PubMed ID: 20821013
[TBL] [Abstract][Full Text] [Related]
18. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
Calais J; Dubray B; Nkhali L; Thureau S; Lemarignier C; Modzelewski R; Gardin I; Di Fiore F; Michel P; Vera P
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):858-67. PubMed ID: 25680400
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer.
Blencowe NS; Whistance RN; Strong S; Hotton EJ; Ganesh S; Roach H; Callaway M; Blazeby JM
Br J Cancer; 2013 Sep; 109(6):1445-50. PubMed ID: 23963146
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating lung cancer recurrence.
Asai N; Ohkuni Y; Shoji K; Kaneko N
J Bras Pneumol; 2013; 39(2):242-4. PubMed ID: 23670511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
